文献速递前列腺增生与排尿功能障碍

Aquablation 治疗大体积前列腺(80-150 mL)所致良性前列腺增生下尿路症状:WATER II 5 年临床试验最终结果

Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results.
PubMed 文献 · J Urol · 2023-04-28

WATER II 是一项前瞻性多中心国际试验(NCT03123250),纳入 101 例中重度良性前列腺增生症状且前列腺体积 80-150 mL 的男性,接受机器人辅助 Aquablation 手术,报告 5 年最终结果。研究在 3 个月时达到安全性与有效性目标,5 年时症状与尿流率持续改善,5 年免于再次良性前列腺增生手术的比例为 96.3%。

要点

  • 5 年时国际前列腺症状评分(IPSS)由基线 22.6 降至 6.8,变化 15.9(P < .001)
  • 5 年时最大尿流率由 8.6 mL/s 增至 17.1 mL/s,变化 9.2 mL/s(P < .001)
  • 5 年免于再次良性前列腺增生手术的比例为 96.3%(Kaplan-Meier 法)

核心结论

  • 在前瞻性随访 5 年时,Aquablation 手术对前列腺体积 80-150 mL 的男性被显示为安全,疗效持久且再治疗率低。

研究设计与样本

  • 前瞻性多中心国际试验(NCT03123250),共 101 例中重度良性前列腺增生症状且前列腺体积 80-150 mL 的男性接受机器人辅助 Aquablation 手术,报告 5 年最终结果。

主要发现

  • 基线平均前列腺体积为 107 mL(范围 80-150)。
  • 平均(SD)国际前列腺症状评分由基线 22.6(6.4)降至 5 年时 6.8(4.6),变化评分为 15.9(7.7,P < .001)。
  • 平均最大尿流率由 8.6(SD 3.4)mL/s 增至 5 年时 17.1(9.8)mL/s,5 年时变化评分为 9.2(11.1)mL/s(P < .001)。
  • 对所有时间点至 5 年的 PSA 变化作为基线 PSA 函数的回归分析显示降低 50%。
  • 以基线前列腺体积 100 mL 为切点的预设亚组分析显示,至 5 年时疗效结局无差异。

关键数值与推荐

  • 研究在 3 个月时成功达到安全性与有效性目标,该目标基于通常在较小前列腺中实施的经尿道前列腺电切术结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report 5-year safety and efficacy outcomes of the Aquablation procedure for the treatment of men with symptomatic benign prostatic hyperplasia and large-volume prostate glands. MATERIALS AND METHODS: A total of 101 men with moderate to severe benign prostatic hyperplasia symptoms and prostate volumes between 80 and 150 mL underwent a robotic-assisted Aquablation procedure in a prospective multicenter international trial (NCT03123250). Herein we report the final 5-year results. RESULTS: The study successfully met its safety and efficacy performance goal, which was based upon transurethral resection of the prostate outcomes typically done in smaller prostates, at 3 months. Mean prostate volume was 107 mL (range 80-150) at baseline. Patient symptoms showed a significant improvement where the mean (SD) International Prostate Symptom Score of 22.6 (6.4) at baseline to 6.8 (4.6) at 5 years, resulting in a change score of 15.9 (7.7, P < .001). Uroflowmetry measurements also demonstrated improvement where the mean maximum urinary flow rate increased from 8.6 (SD 3.4) to 17.1 (9.8) mL/s at 5 years, resulting in a change score of 9.2 (11.1) mL/s at 5 years (P < .001). A regression analysis evaluating change in PSA as a function of baseline PSA across all time points out to 5 years resulted in a 50% reduction. A prespecified subgroup analysis using a baseline prostate volume cutoff of 100 mL showed no difference in efficacy outcomes through 5 years. Freedom from a secondary benign prostatic hyperplasia procedure at 5 years was 96.3% based on Kaplan-Meier. CONCLUSIONS: At 5-years of prospective follow-up, the Aquablation procedure was shown to be safe with durable efficacy and low rates of retreatment in men with large prostates (80-150 mL).

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Bhojani N, Bidair M, Kramolowsky E, et al. Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results. J Urol. 2023. PMID: 37115632. doi:10.1097/JU.0000000000003483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。